Crossmark

How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma

Crossref DOI link: https://doi.org/10.1186/s12955-018-0851-9

Published Online: 2018-01-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hyland, Michael E. https://orcid.org/0000-0003-3879-0469
Lanario, Joseph W.

Pooler, Jill

Masoli, Matthew

Jones, Rupert C.
Funding

Funding for this research was provided by:

AstraZeneca
More Information

Article History

Received: 14 September 2017

Accepted: 19 January 2018

First Online: 27 January 2018

Ethics approval and consent to participate

: Ethical approval was obtained to construct and evaluate a quality of life scale for severe asthma, details: REC ref.: 16/NE/0188; IRAS ID: 207,601. The research was sponsored by Plymouth Hospitals NHS Trust. All patients gave written informed consent.

: Not applicable

: Author MH has received personal fees from Novartis and GSK. Author RJ reports personal fees from GSK, AstraZeneca, Boehringer-Ingelheim, Chiesi, Cipla, Novartis and Pfizer, and research grants from Astra Zeneca. Author MM reports personal fees from Novartis and GSK and grants from Astrazenca. Authors JL reports he has no competing interests. Author JP reports she has no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.